Loading...

Medigene AG

0QGJ.L•LSE
Healthcare
Biotechnology
£0.09
£-0.10(-51.35%)

Medigene AG (0QGJ.L) Stock Overview

Explore Medigene AG’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 60.8/100

Key Financials

Market Cap1.2M
P/E Ratio-0.07
EPS (TTM)$-0.41
ROE-0.78%
Fundamental Analysis

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 Months$1.36
1 Year Target$1.05

0QGJ.L Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Medigene AG (0QGJ.L) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 23.25, suggesting the stock is in an oversold condition. Our forecasting models predict significant price movements, with a 12-month target of $1.05.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.07 and a market capitalization of 1.2M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

23.25RSI (14)
-0.02MACD
82.74ADX
Stats data is not available for 0QGJ.LStats details for 0QGJ.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for 0QGJ.LAnalyst Recommendations details for 0QGJ.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Medigene AG, a biotechnology company, focuses on the development of T cell immunotherapies for the treatment of cancer. The company is developing personalized T cell-based therapies with a focus on T cell receptor-modified T cells in the areas of unmet medical needs, which are in clinical development. It also focuses on dendritic cell vaccines and T cell-specific monoclonal antibodies. In addition, the company focuses on developing and marketing RhuDex for hepatology and gastroenterology indications. Medigene AG has a strategic partnership with 2seventy bio, Inc. for the development of T cell receptors. The company also has research collaboration agreements on novel cancer antigens for immunotherapies with the Université de Montréal; and with Cytovant Sciences Co. Ltd. It has operations in Europe, the United States, Asia, and internationally. The company was founded in 1994 and is headquartered in Munich, Germany.

CEO

Selwyn Ho MB BS, MBBS

Employees

87

Headquarters

Lochhamer Strasse 11, Munich

Founded

2007

Frequently Asked Questions

;